CCAB part of Core platform funded by Terry Fox Research Institute’s Program Grant to design novel brain cancer therapies
A team of lead researchers including University of Toronto’s Drs. Sachdev Sidhu and Jason Moffat, and McMaster University’s Dr. Sheila Singh, was recently awarded a prestigious Terry Fox Research Institute (TFRI) New Frontiers Program Project Grant to develop antibody-based therapies for brain cancer (glioblastoma, or GBM).
The Program includes several Core platforms, one of which is the Toronto Recombinant Antibody Centre (TRAC) that will generate antibody candidates to be tested in GBM models. CCAB is proud to contribute its IgG production capabilities to the platform.
The Core platform was recently featured in a blog post by TFRI. Read it here.